FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360606475> ?p ?o ?g. }

• W4360606475 abstract "You have accessJournal of UrologyCME1 Apr 2023MP15-09 TADALAFIL VERSUS COMBINED TAMSOLUSIN AND CIPROFLOXACIN FOR TREATMENT OF CHRONIC PELVIC PAIN SYNDROME: A RANDOMIZED CONTROLLED TRIAL Marwan Anas, Ahmed EL-Hefnawy, and Ahmed Shoma Marwan AnasMarwan Anas More articles by this author , Ahmed EL-HefnawyAhmed EL-Hefnawy More articles by this author , and Ahmed ShomaAhmed Shoma More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003235.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Chronic prostatitis /Chronic pelvic pain syndrome (CP/CPPS) is still presenting true considerable challenge to urologists .It is characterized by confluence of symptoms including mainly suprapubic or deep perineal pain, and voiding symptoms. The exact etiology and pathogenesis of CP/CPPS remain unknown up till now. A specific diagnostic test for CP/CPPS is still not yet determined. Until now, there are no proven therapies for CP/CPPS. A wide variety of pharmacologic and non-pharmacologic therapies have been studied in clinical trials, but most have shown limited curative efficacy in symptom alleviation. Our aim To assess the efficacy and safety of PDEI-5 (Tadalafil) for treatment of CP/CPPS. METHODS: It is a prospective randomized controlled single blinded phase III clinical trial. Between May 2020 and April 2022, 97 patients with a diagnosis of type IIIa chronic non-bacterial prostatitis were enrolled in the final analysis at the end of study. Forty-nine for tadalafil (group A), who received combined tadalafil 5 mg once daily before bed time and placebo (sugar pills) after meal once daily for 12 weeks and forty-eight for combined tamsulosin and ciprofloxacin (group B) who received ciprofloxacin 1000 mg once daily PO after meal and tamsulosin 0.4 mg before bed time for the same period. Patients were followed for 12 weeks after administration of treatment. Primary end point was pain relief which was assessed by NIH-CPSI at 12 weeks after treatment. RESULTS: Patients baseline characteristics were comparable in both groups. At the end of RCT, tadalafil-group patients showed significant improvement in total, pain, urinary and Qol domains of NIH-CPSI compared to baseline (17.92±2.3, 7.41±1.56, 4.96±0.86, 5.55±0.79 vs. 30.88±3.62, 14.67±2.2, 6.67±1.17, 9.53±1.15 respectively, p<0.0001). When compared to combined tamsulosin and ciprofloxacin, all 12th week NIH-CPSI domains scores, except for urinary, were significantly better in tadalafil group (p<0.0001). Side-effects among group B were much higher than in group A. The most common side-effects in group A were dyspepsia (8.2%) and back pain (6.1%) while in group B were retrograde ejaculation (18.8%) and dizziness (16.7%). By the end of 12th week, 39 (79.6%) patients in group A showed marked improvement in GRA, while in group B, 41 (85.4%) patients showed moderate improvement. CONCLUSIONS: Tadalafil is effective and safe treatment modality for CP/CPPS. It has the advantage of giving more pain relief and improvement of sexual function compared with combined tamsulosin and ciprofloxacin. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e195 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Marwan Anas More articles by this author Ahmed EL-Hefnawy More articles by this author Ahmed Shoma More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360606475 created "2023-03-24" @default.
• W4360606475 creator A5008884809 @default.
• W4360606475 creator A5026728930 @default.
• W4360606475 creator A5077843293 @default.
• W4360606475 date "2023-04-01" @default.
• W4360606475 modified "2023-09-29" @default.
• W4360606475 title "MP15-09 TADALAFIL VERSUS COMBINED TAMSOLUSIN AND CIPROFLOXACIN FOR TREATMENT OF CHRONIC PELVIC PAIN SYNDROME: A RANDOMIZED CONTROLLED TRIAL" @default.
• W4360606475 doi "https://doi.org/10.1097/ju.0000000000003235.09" @default.
• W4360606475 hasPublicationYear "2023" @default.
• W4360606475 type Work @default.
• W4360606475 citedByCount "0" @default.
• W4360606475 crossrefType "journal-article" @default.
• W4360606475 hasAuthorship W4360606475A5008884809 @default.
• W4360606475 hasAuthorship W4360606475A5026728930 @default.
• W4360606475 hasAuthorship W4360606475A5077843293 @default.
• W4360606475 hasConcept C121608353 @default.
• W4360606475 hasConcept C126322002 @default.
• W4360606475 hasConcept C141071460 @default.
• W4360606475 hasConcept C142724271 @default.
• W4360606475 hasConcept C168563851 @default.
• W4360606475 hasConcept C204787440 @default.
• W4360606475 hasConcept C27081682 @default.
• W4360606475 hasConcept C2776235491 @default.
• W4360606475 hasConcept C2776362571 @default.
• W4360606475 hasConcept C2779929075 @default.
• W4360606475 hasConcept C2780136519 @default.
• W4360606475 hasConcept C2780524745 @default.
• W4360606475 hasConcept C2780816001 @default.
• W4360606475 hasConcept C71924100 @default.
• W4360606475 hasConceptScore W4360606475C121608353 @default.
• W4360606475 hasConceptScore W4360606475C126322002 @default.
• W4360606475 hasConceptScore W4360606475C141071460 @default.
• W4360606475 hasConceptScore W4360606475C142724271 @default.
• W4360606475 hasConceptScore W4360606475C168563851 @default.
• W4360606475 hasConceptScore W4360606475C204787440 @default.
• W4360606475 hasConceptScore W4360606475C27081682 @default.
• W4360606475 hasConceptScore W4360606475C2776235491 @default.
• W4360606475 hasConceptScore W4360606475C2776362571 @default.
• W4360606475 hasConceptScore W4360606475C2779929075 @default.
• W4360606475 hasConceptScore W4360606475C2780136519 @default.
• W4360606475 hasConceptScore W4360606475C2780524745 @default.
• W4360606475 hasConceptScore W4360606475C2780816001 @default.
• W4360606475 hasConceptScore W4360606475C71924100 @default.
• W4360606475 hasIssue "Supplement 4" @default.
• W4360606475 hasLocation W43606064751 @default.
• W4360606475 hasOpenAccess W4360606475 @default.
• W4360606475 hasPrimaryLocation W43606064751 @default.
• W4360606475 hasRelatedWork W2016889548 @default.
• W4360606475 hasRelatedWork W2142227426 @default.
• W4360606475 hasRelatedWork W2142820536 @default.
• W4360606475 hasRelatedWork W2303076182 @default.
• W4360606475 hasRelatedWork W2598716865 @default.
• W4360606475 hasRelatedWork W2979592670 @default.
• W4360606475 hasRelatedWork W2979972401 @default.
• W4360606475 hasRelatedWork W3041636644 @default.
• W4360606475 hasRelatedWork W3147563318 @default.
• W4360606475 hasRelatedWork W4252724721 @default.
• W4360606475 hasVolume "209" @default.
• W4360606475 isParatext "false" @default.
• W4360606475 isRetracted "false" @default.
• W4360606475 workType "article" @default.